Marksans Pharma Limited

17%

um, we have another strong quarter both in terms of revenue and operating margins. Revenue grew by 17% YoY in Q2 led by increased demand and market share gains across our key regions. We continue to re

₹ 531.2

, and we will strive to maintain and build upon this upward trajectory in the upcoming quarters.” ₹ 531.2 cr +17.4% (YoY) ₹ 113.9 cr +41.9% (YoY) Q2FY24 Revenue Q2FY24 EBITDA ₹ 83.9 cr +39.5% (Yo

17.4%

l strive to maintain and build upon this upward trajectory in the upcoming quarters.” ₹ 531.2 cr +17.4% (YoY) ₹ 113.9 cr +41.9% (YoY) Q2FY24 Revenue Q2FY24 EBITDA ₹ 83.9 cr +39.5% (YoY) Q2FY2

₹ 113.9

ntain and build upon this upward trajectory in the upcoming quarters.” ₹ 531.2 cr +17.4% (YoY) ₹ 113.9 cr +41.9% (YoY) Q2FY24 Revenue Q2FY24 EBITDA ₹ 83.9 cr +39.5% (YoY) Q2FY24 PAT Mark Saldan

41.9%

ld upon this upward trajectory in the upcoming quarters.” ₹ 531.2 cr +17.4% (YoY) ₹ 113.9 cr +41.9% (YoY) Q2FY24 Revenue Q2FY24 EBITDA ₹ 83.9 cr +39.5% (YoY) Q2FY24 PAT Mark Saldanha M A N

₹ 83.9

g quarters.” ₹ 531.2 cr +17.4% (YoY) ₹ 113.9 cr +41.9% (YoY) Q2FY24 Revenue Q2FY24 EBITDA ₹ 83.9 cr +39.5% (YoY) Q2FY24 PAT Mark Saldanha M A N A G I N G D I R E C TO R A N D C E O ₹ 661 cr

39.5%

” ₹ 531.2 cr +17.4% (YoY) ₹ 113.9 cr +41.9% (YoY) Q2FY24 Revenue Q2FY24 EBITDA ₹ 83.9 cr +39.5% (YoY) Q2FY24 PAT Mark Saldanha M A N A G I N G D I R E C TO R A N D C E O ₹ 661 cr as of Sep

₹ 661

A ₹ 83.9 cr +39.5% (YoY) Q2FY24 PAT Mark Saldanha M A N A G I N G D I R E C TO R A N D C E O ₹ 661 cr as of September 30th, 2023 Cash Balance 5 Financial Highlights Q2FY24 – YoY Performance ₹ Cr

52.4%

2.6 17.4% Gross Profit Gross Margin % EBITDA EBITDA Margin % PAT Net Profit Margin % 278.5 52.4% 113.9 21.4% 83.9 15.2% 229.4 50.7% 80.3 17.7% 60.1 12.9% 21.4% 41.9% 39.5% Revenue gr

21.4%

oss Profit Gross Margin % EBITDA EBITDA Margin % PAT Net Profit Margin % 278.5 52.4% 113.9 21.4% 83.9 15.2% 229.4 50.7% 80.3 17.7% 60.1 12.9% 21.4% 41.9% 39.5% Revenue growth is being

15.2%

ross Margin % EBITDA EBITDA Margin % PAT Net Profit Margin % 278.5 52.4% 113.9 21.4% 83.9 15.2% 229.4 50.7% 80.3 17.7% 60.1 12.9% 21.4% 41.9% 39.5% Revenue growth is being driven by mar

50.7%

EBITDA EBITDA Margin % PAT Net Profit Margin % 278.5 52.4% 113.9 21.4% 83.9 15.2% 229.4 50.7% 80.3 17.7% 60.1 12.9% 21.4% 41.9% 39.5% Revenue growth is being driven by market share gain

For more information please contact

1

For more information please contact

Jitendra Sharma (CFO) Marksans Pharma Ltd Tel: +91 022 40012000 jitendra@marksanspharma.com Corporate Office 11th Floor Grandeur, Off Veera Desai Road, Opp Gundecha Symphony, Andheri (W), Mumbai – 400 053, Maharashtra - India © 2020 Marksans Pharma Limited, All Rights Reserved. “Marksans Pharma” and The Marksans Pharma Logo are trademarks of Marksans Pharma Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.